Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
The significance of serum CA-125 and various tumour markers in pulmonary and pleural tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 156s Year: 2003
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013
Different prevalence of positivity for human mammaglobin (hMAM) transcipts in the pleural fluid of patients with malignant vs. non malignant pleural disease Source: Eur Respir J 2006; 28: Suppl. 50, 580s Year: 2006
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008